Stephen Algeo, MD
Cardiovascular Disease · Tucson, AZNPI 1487632212
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,889 of the $53,186 with a category attached, or 80.6%. Johnson & Johnson accounts for 61.5% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $20,205 and has fallen 93.7% since, to $1,263 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 773 payments — averaging $68.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$33K
- Amgen$13K
- Novartis$2K
- Boston Scientific$815
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$796
- Abbott$658
- plus $4K from 29 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$42,88981%
- Food & beverage$9,99719%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 164 | $32,709 |
| Amgen | 62 | $12,724 |
| Novartis | 171 | $1,524 |
| Boston Scientific | 16 | $815 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 46 | $796 |
| Abbott | 97 | $658 |
| Pfizer | 41 | $574 |
| Merck | 25 | $440 |
| Boehringer Ingelheim | 19 | $304 |
| Actelion Pharmaceuticals US, Inc. | 5 | $271 |
| Edwards Lifesciences | 5 | $254 |
| E.r. Squibb & Sons, L.L.C. | 17 | $231 |
| AstraZeneca | 13 | $230 |
| Amarin Pharma, Inc. | 13 | $195 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $183 |
| Alnylam Pharmaceuticals Inc. | 10 | $170 |
| Kestra Medical Technology Services, Inc. | 5 | $157 |
| Sanofi-aventis U.S. LLC | 10 | $154 |
| Impulse Dynamics (USA) Inc. | 8 | $133 |
| Medtronic | 8 | $125 |
| Astellas Pharma US Inc | 6 | $81 |
| Shockwave Medical, Inc | 3 | $79 |
| Esperion Therapeutics, Inc. | 4 | $67 |
| Philips North America LLC | 1 | $63 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Bardy Diagnostics, Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 2 | $24 |
| Janssen Scientific Affairs, LLC | 3 | $22 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Gilead | 1 | $13 |
| Cvrx, Inc. | 1 | $11 |
| Watermark Medical, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$31,330
- Repatha$12,109
- Watchman$359
- UPTRAVI$250
- OPSUMIT$250
- WATCHMAN Access System$232
- SAPIEN 3 Ultra RESILIA$133
How this compares
$53,186 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 537 | $715,248 |
| XareltoRivaroxaban | 449 | $525,001 |
| EntrestoSacubitril/Valsartan | 224 | $287,095 |
| Repatha SureclickEvolocumab | 165 | $186,881 |
| JardianceEmpagliflozin | 75 | $109,438 |
| FarxigaDapagliflozin Propanediol | 41 | $37,070 |
| MultaqDronedarone Hcl | 19 | $31,605 |
| Repatha SyringeEvolocumab | 14 | $17,808 |
| NexletolBempedoic Acid | 17 | $15,386 |
| Flecainide Acetate | 269 | $13,913 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $12,805 |
| BrilintaTicagrelor | 11 | $9,893 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 25 | $8,911 |
| Ezetimibe | 296 | $6,714 |
| SavaysaEdoxaban Tosylate | 13 | $6,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $574 | $715,248537 claims |
| Johnson & JohnsonXarelto | $32,709 | $525,001449 claims |
| NovartisEntresto | $1,524 | $287,095224 claims |
| Boehringer IngelheimJardiance | $304 | $109,43875 claims |
| AstraZenecaFarxiga, Brilinta | $230 | $46,96352 claims |
| Sanofi-aventis U.S. LLCMultaq | $154 | $31,60519 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $67 | $28,19128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Tucson
- Steven MottlTucson$340K
- Karl KernTucson$174K
- Marvin SlepianTucson$106K
- Monty MoralesTucson$39K
- Hoang ThaiTucson$30K
- Joshua BeverlyTucson$24K
- Paul FensterTucson$22K
- Gundeep SinghTucson$18K
- Rajen DesaiTucson$16K
- Paul BejaranoTucson$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.